Halsey
Executive Summary
Selling ANDA for oxycodone 5 mg/acetaminophen 325 mg tablets to Mallinckrodt. Halsey received $500,000 on signing the letter of intent and expects to get "several million" dollars when deal is completed. Mallinckrodt also agrees to extend credit to Halsey for certain raw material purchases. The funds from the sale will be used to reduce Halsey's outstanding debt. The generic company announces that its banks have extended Halsey's credit agreement to Dec. 31. Under an agreement announced in April, the banks will waive certain defaults under Halsey's restructed loan agreements
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth